Se­r­i­al en­tre­pre­neur Gary Glick sells an­oth­er one of his star­tups for $229M — this time to an un­like­ly buy­er

Gary Glick has proven him­self, time and again, a nifty start­up artist. Af­ter sell­ing Lyc­era to Cel­gene, he held a streak for IFM Ther­a­peu­tics — carv­ing a plate of in­flam­ma­tion pro­grams each time and turn­ing the re­sult­ing sub­sidiary over to Big Phar­ma, while keep­ing the core dis­cov­ery unit — and more re­cent­ly lined up $270 mil­lion for pre­ci­sion on­col­o­gy work at Scor­pi­on.

His lat­est deal, though, looks a bit dif­fer­ent.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN